Bio-Techne Corp SEC Filings

Bio-Techne (TECH) reported insider transactions by its CFO on 11/03/2025. The executive acquired company stock through RSU vesting and surrendered shares to cover taxes.

Two RSU conversions (code M) added 13,159 shares and 11,545 shares at $0. A tax withholding transaction (code F) disposed of 11,865 shares at $62.57. Following these transactions, the CFO directly owned 142,722 shares.

These actions reflect routine equity award vesting and associated tax settlement rather than an open‑market purchase or sale.

Bio‑Techne (TECH) reported an insider equity event by its President, Protein Sciences. On 11/03/2025, 9,911 shares were acquired at $0 upon settlement of restricted stock units, followed by the disposition of 4,520 shares at $62.57, typically associated with tax withholding. After these transactions, the officer directly owned 20,503 common shares.

The filing also lists outstanding equity awards, including stock options with expirations through 2035 and various time- and performance-based RSUs, indicating future vesting schedules tied to service and performance conditions.

Bio‑Techne (TECH) reported Q1 FY2026 results. Net sales were $286.6 million versus $289.5 million a year ago as Protein Sciences softened while Diagnostics & Spatial Biology improved organically. Gross margin rose to 65.6% from 63.2%, and operating income increased to $47.7 million from $40.0 million. Net earnings were $38.2 million with diluted EPS of $0.24, up from $0.21.

Cash flow from operations was $27.6 million. Cash and equivalents were $145.0 million, and long‑term debt decreased to $300.0 million from $346.0 million, reflecting $46.0 million in repayments. Segment detail: Protein Sciences sales were $202.2 million (down 1%), operating margin 38.4%; Diagnostics & Spatial Biology sales were $79.5 million (down 4% reported; organic growth 3%), operating margin 11.2% versus 5.1%. The quarter included a $6.8 million recovery related to the Exosome Diagnostics divestiture and receipt of MDxHealth stock valued at $8.7 million. EMEA (ex‑UK) grew, while the United States declined year over year.

Bio‑Techne Corporation filed an 8‑K reporting that it issued a press release describing results of operations for the quarter ended September 30, 2025 and its financial condition as of that date. The company also announced via a separate press release that its Board declared a cash dividend.

Shareholders held the Annual Meeting with a quorum of 140,827,559 shares, representing approximately 90.45% of outstanding shares. Shareholders set the number of directors at nine (For 140,278,598; Against 314,005; Abstain 234,956), and elected all nine nominees by a majority standard. The advisory vote on executive compensation passed (For 100,792,824; Against 39,025,321; Abstain 1,009,414). Shareholders ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending June 30, 2026 (For 137,578,559; Against 3,055,503; Abstain 193,497).

Bio-Techne Corp (TECH) reported an insider equity transaction by a director. On 10/30/2025, the reporting person acquired 1,640 shares of common stock at $0 and received a grant of stock options for 3,777 shares at an exercise price of $60.96, expiring on 10/30/2035.

After these transactions, the director directly beneficially owns 8,775 shares of common stock. The option grant vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.

Bio‑Techne (TECH) director reported equity changes on 10/30/2025. The filing shows an acquisition of 1,640 shares of Common Stock at $0, bringing direct holdings to 15,411 shares. It also reports a new grant of 3,777 stock options with an exercise price of $60.96 and an expiration on 10/30/2035. According to the note, this option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio‑Techne’s 2026 annual meeting of shareholders.

Bio-Techne (TECH) director John L. Higgins filed a Form 4 reporting equity awards dated 10/30/2025. He acquired 1,640 shares of common stock at $0, bringing his directly held common stock to 66,876 shares after the transaction. He was also granted stock options for 3,777 shares with an exercise price of $60.96, expiring on 10/30/2035. The options vest on the earlier of the one‑year anniversary of the grant date or Bio‑Techne’s 2026 annual meeting of shareholders.

Bio-Techne (TECH) director Alpna Seth reported insider transactions. On 10/30/2025, she acquired 1,640 shares of common stock at $0, bringing her direct holdings to 15,411 shares. She also received a new stock option grant for 3,777 shares at an exercise price of $60.96, expiring on 10/30/2035. The option vests on the earlier of the one-year anniversary of the grant date or the company’s 2026 annual meeting of shareholders.

Bio‑Techne (TECH): Form 4 insider update. Director Amy E. Herr reported an equity grant on 10/30/2025. She acquired 1,640 shares of common stock at $0, bringing direct holdings to 2,680 shares; an additional 2,154 shares are held indirectly by a significant other.

She was also granted a stock option to buy 3,777 shares at $60.96, expiring 10/30/2035; vesting occurs on the earlier of the one‑year anniversary of the grant or the 2026 annual meeting. The filing also lists previously awarded options and restricted stock units held indirectly with specified vesting schedules.